China Resources Pharmaceutical Group Management
Management criteria checks 3/4
China Resources Pharmaceutical Group's CEO is Xiaosong Bai, appointed in Jan 2022, has a tenure of 2.33 years. total yearly compensation is CN¥2.55M, comprised of 98% salary and 2% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth HK$1.01M. The average tenure of the management team and the board of directors is 2.5 years and 3.9 years respectively.
Key information
Xiaosong Bai
Chief executive officer
CN¥2.6m
Total compensation
CEO salary percentage | 98.0% |
CEO tenure | 2.3yrs |
CEO ownership | 0.003% |
Management average tenure | 2.5yrs |
Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | CN¥4b |
Sep 30 2023 | n/a | n/a | CN¥4b |
Jun 30 2023 | n/a | n/a | CN¥4b |
Mar 31 2023 | n/a | n/a | CN¥4b |
Dec 31 2022 | CN¥3m | CN¥2m | CN¥4b |
Compensation vs Market: Xiaosong's total compensation ($USD352.29K) is below average for companies of similar size in the Hong Kong market ($USD575.18K).
Compensation vs Earnings: Insufficient data to compare Xiaosong's compensation with company performance.
CEO
Xiaosong Bai (52 yo)
2.3yrs
Tenure
CN¥2,550,953
Compensation
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 1.0m | |
VP & Executive Director | 2.7yrs | CN¥2.76m | no data | |
CFO & Executive Director | less than a year | no data | no data | |
Chief Information Officer & VP | 10.4yrs | no data | no data | |
Chief Legal Advisor | 10.2yrs | no data | no data | |
Company Secretary | less than a year | no data | no data | |
Vice President | no data | no data | no data | |
Vice President of CR Pharma & Chairman of China Resources Boya | no data | no data | no data |
2.5yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 3320's management team is considered experienced (2.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 1.0m | |
VP & Executive Director | 2.7yrs | CN¥2.76m | no data | |
CFO & Executive Director | less than a year | no data | no data | |
Independent Non-Executive Director | 7.9yrs | CN¥265.08k | no data | |
Non-Executive Director | 2.3yrs | no data | no data | |
Independent Non-Executive Director | 7.9yrs | CN¥265.08k | no data | |
Independent Non-Executive Director | 7.9yrs | CN¥265.08k | no data | |
Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.4yrs | no data | no data | |
Non-Executive Director | 1.3yrs | no data | no data | |
Independent Non-Executive Director | 6.8yrs | CN¥265.08k | no data | |
Chairman | 4.6yrs | CN¥2.62m | 0.0048% CN¥ 1.5m | |
Non-Executive Director | 3.2yrs | no data | no data |
3.9yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 3320's board of directors are considered experienced (3.9 years average tenure).